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To evaluate the association of rainy season with overall dengue disease incidence and with
the efficacy of the Sanofi Pasteur recombinant, live, attenuated, tetravalent vaccine (CYD-
TDV) in two randomized, controlled multicenter phase III clinical trials in Asia and Latin
America.
Methods
Rainy seasons were defined for each study site using climatological information from the
World Meteorological Organization. The dengue attack rate in the placebo group for each
study month was calculated as the number of symptomatic, virologically-confirmed dengue
events in a given month divided by the number of participants at risk in the same month.
Time-dependent Cox proportional hazard models were used to test whether rainy season
was associated with dengue disease and whether it modified vaccine efficacy in each of the
two trials and in both of the trials combined.
Findings
Rainy season, country, and age were all significantly associated with dengue disease in
both studies. Vaccine efficacy did not change during the rainy season in any of the
analyses.
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Conclusions
Although dengue transmission and exposure are expected to increase during the rainy sea-
son, our results indicate that CYD-TDV vaccine efficacy remains constant throughout the
year in endemic regions.
Introduction
Dengue is a mosquito-transmitted viral disease found in tropical and subtropical areas, as
well as some temperate regions of the United States, Europe, Africa, and the Middle East
[1]. Almost 4 billion people are estimated to be at risk for dengue infection in more than
100 countries around the world [2]. In recent decades, the number of reported dengue cases
has dramatically increased, making dengue a disease of global public health importance.
Dengue infection is usually asymptomatic but also has a wide spectrum of clinical manifes-
tations. Of the estimated 390 million children and adults infected each year, 96 million
exhibit clinical disease [3]. Clinical dengue disease includes influenza-like symptoms, skin
rash, and more severe manifestations such as severe plasma leakage, severe bleeding, and
severe organ impairment. Four antigenically different serotypes of dengue virus exist; sec-
ondary infection with a heterologous serotype has been shown to be a risk factor for severe
dengue [4–6].
Dengue prevention consists primarily of measures that aim to control the Aedes aegypti or
Aedes albopictus vector, such as habitat elimination to reduce the risk of mosquito bites [7].
However, these measures have had limited ability to protect against disease as outbreaks still
occur frequently. Moreover, there is currently no specific antiviral treatment against dengue,
although several dengue vaccines are in development [8]. The recombinant live attenuated tet-
ravalent vaccine (CYD-TDV) developed by Sanofi Pasteur has been tested in two phase III effi-
cacy trials: one placebo-controlled phase III trial of the CYD-TDV dengue vaccine was
conducted in 2–14 year olds in South East Asia with the active surveillance phase lasting from
June 2011 to December 2013 (CYD14) [9] and another phase III trial conducted in 9–16 year
olds in Latin America with the active surveillance phase lasting from June 2011 to April 2014
(CYD15) [10] (the phase III trials are discussed further in [11]). In both trials, after randomiza-
tion of children to receive vaccine or placebo at 0,6 and 12 months, active surveillance for
symptomatic virologically-confirmed dengue (VCD) followed over 25 months after the first
injection. The overall intent-to-treat vaccine efficacy (VE) was 54.8% (95%CI 46.8, 61.7) and
VE against severe dengue 70% (95%CI 35.7, 86.6) in Asia versus 64.7% (95%CI 58.7, 69.8) and
95.5% (95%CI 68.8, 99.9) respectively in Latin America during this active phase. These find-
ings supported the licensing of CYD-TDV in several dengue endemic countries where the
seroprevalence rate is more than 70% [11].
Variation of VE was observed depending on the seroprevalence in the countries: for exam-
ple, in CYD15, seroprevalence was higher in Brazil and Colombia than in Mexico and Puerto
Rico (55.5%, 92.5%, 50.9% and 48.9% respectively), and so was efficacy (77.5%, 67.5%, 31.3%
and 57.6% respectively) [10,12]. In exploratory analyses of CYD14 and CYD15, estimated VE
was higher for older children and for children who were seropositive to at least one dengue
serotype at baseline compared to children who were seronegative [9, 10]. Moreover, during
the year 3 of the long-term safety follow-up in CYD14, an excess in the number of dengue hos-
pitalization and/or severe cases was found in the vaccinated younger age group (2 to 5 years
old). Sanofi Pasteur performed additional analyses of long term follow up safety data to better
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com.
Funding: CP was paid by Ecole Normale Supérieur
de Cachan and supported by Vaccine Research
Institute (http://vaccine-research-institute.fr/en/).
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript. MEH is partially
supported by National Institute of Allergy and
Infectious Diseases/NIH R37 AI032042. Sanofi
Pasteur (http://www.sanofipasteur.com/en/)
provided support in the form of salaries for authors
[EL, RLO, CF, MC, LC] or indirectly as funding to
the institutions to support the work in CYD14 and
CYD15 trials [ZM, PBG, PP, MRC, GC], but did not
have any additional role in the study design, data
collection and analysis, decision to publish, or
preparation of the manuscript. The specific roles of
these authors are articulated in the ‘author
contributions’ section.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests; ZM, MEH and PG
were funded by contracts from Sanofi Pasteur. EL,
RLO, MC, CF and LC are employees of Sanofi
Pasteur. GC was employed as a Principal
Investigator Coordinator by Fundacion Santa Fe de
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understand whether these findings were due to age effect or previous exposure to dengue [13]
and to assess the potential risk and/or benefit of vaccination of baseline-seronegative individu-
als. These analyses indicated that while vaccination in endemic areas confers predicted benefit
on the population level, the vaccine performs differently in seropositive vs seronegative indi-
viduals, with baseline-seronegative individuals receiving the vaccine showing increased risk of
hospitalized and severe dengue compared to placebo recipients, starting about 30 months
post-first dose [14]. It is not clear if the possible age effect may be associated with pre-existing
dengue exposure or age-specific differences (e.g. less-developed vascular physiology or imma-
ture immune responses in the younger age group). The World Health Organization thus con-
cluded that a “‘prevaccination screening strategy’ would be the preferred option, in which only
dengue-seropositive-persons are vaccinated [14].” However, no point-of care diagnostic test is
currently available that would allow rapid, sensitive, and specific prevaccination screening to
determine baseline serostatus; the development of such a test has been outlined as a high
research priority [12].
A question of interest is whether VE varies according to dengue transmission intensity.
There is a prevailing view in general vaccinology that, in the setting of a “leaky vaccine”, VE
may be reduced during periods of high exposure [15]. It has been underlined that in the con-
text of infectious diseases, the temporal pattern of the varying risks of infection should be
accounted for in the evaluation of vaccine efficacy, e.g. for the DTaP pertussis vaccine [16], for
which vaccine efficacy was suggested to be lower during periods of higher exposure [17]. In an
additional study on the RV144 HIV vaccine, a significant effect modification was seen in
behavioral risk status over time and VE where VE was 68% for participants who maintained
low or medium risk but only 5% for the high risk group [18]. In an earlier trial among Thai
injecting drug users, Vax 003, of the same AIDSVAX B/E component as RV144, it is hypothe-
sized that the lack of VE may have been due to the stringency of intravenous challenge when
compared with the intravaginal and intrarectal routes of RV144 [19]. In the related disease set-
ting of malaria, concerns have also been raised about whether the transmission intensity of the
disease might impact vaccine efficacy [20–22], in particular due to the seasonal variation of the
natural force of infection [23]. To address this question, a study in Malawi evaluated effect
modification of RTS,S/AS01 malaria vaccine efficacy by seasonal precipitation and found there
was none [24]. Similar to malaria transmission, dengue transmission is influenced by many
factors [25–28]; climatic factors such as temperature and rainy season can play a particularly
important role in shaping dengue epidemics and should be carefully considered when studying
these epidemics [29]. Some studies have shown how these factors could be used to predict den-
gue outbreaks [30,31]. Specifically, several pieces of evidence indicate that dengue transmis-
sion is increased at high temperatures. First, A. aegypti or A. albopictus reproduction, bite rate,
and survival all increase with temperature until a cut-off of approximately 32˚C is reached
[32–35]. High temperature also shortens the extrinsic incubation period, such that mosquitoes
become infectious faster [36,37]. Rainy season has also been found to be associated to dengue
transmission [38,39], although the findings can vary between studies and geographic locations
[40]. Nevertheless, rain is believed to increase the number of available breeding sites (e.g.,
water-filled containers) and hence the number of mosquitoes, suggesting increased transmis-
sion during the rainy season. We considered rainy season data to provide a better basis than
temperature data for defining periods of high dengue intensity due to its direct effect on mos-
quito habitats. Thus, we used rainy season as a proxy for the force of dengue infection to evalu-
ate the association of rainy season with overall dengue disease and on the efficacy of the
CYD-TDV vaccine.
Rainy season does not impact dengue vaccine efficacy in endemic regions
PLOS ONE | https://doi.org/10.1371/journal.pone.0207878 December 13, 2018 3 / 16
Methods
Data
We analyzed data from the two primary phase III clinical trials on which CYD-TDV licensure
was based: CYD14, conducted in 10, 275 children in five countries in South East Asia, and
CYD15, conducted in 20,869 children in five countries in Latin America. Children in each trial
were randomly assigned in a 2:1 ratio to receive three injections of either CYD-TDV or pla-
cebo, respectively, at months 0, 6, and 12. Children were followed for symptomatic virologi-
cally-confirmed dengue until month 25 after the first injection. During this period, all children
were under active surveillance. Surveillance consisted of weekly reminders to the family to go
to the health care center if acute febrile illness was observed. In cases of acute febrile illness,
two blood samples were collected for virological confirmation of the presence of dengue. One
sample was collected within 5 days after the onset of fever and the second one was obtained 7
to 14 days later. The first sample was tested for dengue nonstructural protein 1 (NS1) antigen
using an ELISA assay (Platelia Bio-Rad Laboratories, Marnes-La-Coquette, France [41]) and
with a quantitative reverse transcription PCR assay and a serotype-specific PCR assay (Sim-
plexa Dengue Real-Time PCR Assay, Focus Diagnostics, CA, USA). If any of these tests were
positive, the event was considered to be virologically-confirmed dengue. Both the first and the
second samples were tested for dengue IgM and IgG. The first day of the acute febrile illness
was used as the date of virologically-confirmed dengue.
Ethics statement
The trial protocols were approved by all relevant ethics review boards, and parents or guard-
ians provided written informed consent and older children provided written informed assent
before participation, in accordance with local regulations. All patient data were anonymized.
The ethics review boards for CYD14 were the following:
• The Committee of Medical research Ethics, Faculty of Medicine, University of Indonesia,
Jakarta Indonesia
• The Research and Development Unit Medical Faculty University of Udayana, Sanglah Gen-
eral Hospital, Denpasar, Indonesia
• Health Research Ethics Committee, Faculty of medicine University of Padjadjadrain, Dr
Hasan Sadikin hospital, Bandung, Indonesia
• Medical Research and Ethics Committee, Ministry of Health, Malaysia, Kuala Lumpur,
Malaysia
• Research institute for Tropical Medicine IRB, Alabang, Muntinlupa City, Philippines
• Vicente Sotto memorial Medical Center EC, Cebu City, Philippines
• Chong Hua Hospital Institutional Review Board, Cebu City, Philippines
• Walter Reed Army Institute of Research international Review Board (WRAIR IRB), Md,
USA
• The Ethical Review Committee for Research in human Subjects, Ministry of Public Health,
Thailand
• Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok,
Thailand
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• Pasteur Institute EC, Ho Chi Minh City, Vietnam
The ethics review boards for CYD15 were the following:
• Comitê de Ética em Pesquisa do Centro Ciências da Saúde (CCS) da Universidade Federal
do Espı́rito Santo (UFES) (CEP/CCS/UFES)
• Comitê de Ética em Pesquisa em Seres Humanos do Hospital Universitário Onofre Lopes /
RN
• Comitê de Ética em Pesquisa em Seres Humanos do Hospital das Clı́nicas da Universidade
Federal de Goiás
• Comitê de Ética em Pesquisa em Seres Humanos da Universidade Federal de Mato Grosso
do Sul—UFMS
• Comitê de Ética em Pesquisa em Seres Humanos da Universidade Federal do Ceará
• Comissão Nacional de Ética Em Pesquisa—CONEP
• Comité de ética en la Investigación—CAIMED
• Comité Corporativo de Ética en Investigación Fundación Santafe de Bogotá
• Comité de ética en Investigación Biomédica—CDI
• Comité de Ética en Investigación Biomédica (CEIB) de la Unidad de Investigación Cientı́fica
de la UNAH.
• Instituto Nacional de Pediatrı́a Comité de Ética en Investigación
• Instituto Nacional de Pediatrı́a
• Comité Ética y de Investigación—UV Universidad Veracruzana
• Saluz Comité de Investigación y Bioética
• Copernicus Group IRB—CGIRB
ClinicalTrials.gov identifiers: NCT01373281; NCT01374516
WHO Universal Trial Numbers: U1111-1116-4957; U1111-1116-4986
Qualified researchers may request access to patient level data and related study documents
including the clinical study report, study protocol with any amendments, blank case report
form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized
and study documents will be redacted to protect the privacy of trial participants. Further
details on Sanofi’s data sharing criteria, eligible studies, and process for requesting access can
be found at: https://www.clinicalstudydatarequest.com
Analysis
Study cohorts. The CYD14 and CYD15 intent-to-treat (ITT) cohorts consisted of all par-
ticipants who received at least one injection [9,10]. Analysis of the ITT cohort included all
symptomatic, virologically-confirmed dengue events between months 0 and 25 (end of the
active follow-up phase). All analyses right-censored participants at month 25 or at dropout if it
occurred earlier. The combined CYD14 + CYD15 analyses focused on the age range of the
study populations for which CYD-TDV is licensed, 9–16 year-old children. Demographic
characteristics of the population combining the two studies are displayed in S1 Table.
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Descriptive analysis: Attack rates. Plots of the monthly attack rate from June 2011 (the
month in which enrollment began) to the end of the active phase follow-up period are shown
for the placebo and vaccinated groups of CYD14 (Fig 1) and CYD15 (Fig 2). Months were
approximated by 30-day periods. In each month-long interval I, the attack rate was calculated
as the number of symptomatic, virologically-confirmed dengue events in I divided by the
number of participants at risk in I with 95% confidence interval (CI) calculated by Wilson
method of interval estimation for a binomial proportion [42]. Analyses were performed in R
Statistical Software [43] version 3.4.3 with the R binom package [44]. Participants were at risk
for dengue in a given month if the date of enrollment was before the end of that month and
the date of their last contact with study staff or the end of the active phase was after the start of
that month.
Statistical analysis. Cox proportional hazard models with time-varying covariates were
used to determine the association of rainy season with dengue disease and with CYD-TDV
efficacy; the proportional hazards assumption was assessed by considering interactions with
time and assessing plots of the scaled Schoenfeld residuals. The Cox model was selected to
make full use of the time-to-event dengue data and the time-dependent rainy season variable.
The rainy season variable was defined as a binary time-dependent variable equal to 1 during
the rainy season and 0 otherwise. For each site in each country, the rainy season was deter-
mined using climatological information from the World Meteorological Organization
(WMO) [45]. This information was based on monthly averages for the 30-year period from
1981 to 2010; contemporaneous rainfall data for the time period in which the trials occurred
were not available. If rainy season data were not available on the WMO website, they were
obtained from country-specific member websites [46]. Based on this information, the rainy
season was defined as all months with average total precipitation (in mm) greater than the
average monthly precipitation during the year. The site-specific rainy seasons for CYD14 and
CYD15 sites are reported in Fig 3A and 3B, respectively. All models were estimated by adjust-
ing on the baseline covariates sex, protocol-specified age category (2–5, 6–11, 12–14 years in
CYD14; 9–11, 12–16 years in CYD15; 9–11, 12–16 years in combined analysis of CYD14 and
CYD15), and country (using a nominal categorical variable taking values Indonesia, Malaysia,
Philippines, Thailand, and Vietnam in CYD14 and Brazil, Colombia, Honduras, Mexico, and
Puerto Rico in CYD15). The expression of the Cox model for the combined analysis of CYD14
and CYD15 is provided in S1 File and a map of the sites is available in S1 Fig. Analyses were
performed in R Statistical Software version 3.0.1 with the R survival package [47,48]. All p-val-
ues are two-sided with significance declared for p-values below 0.05.
Results
Fig 1 shows the attack rate by month in the placebo (1A) and vaccinated (1B) groups of
CYD14 from June 2011 (start of enrollment) to the end of 2013. A seasonal trend can be
observed in this plot, with a higher attack rate occurring between June and September in both
2012 and 2013. These months correspond to the rainy seasons of the Philippines (where 49%
of the dengue cases occurred), Thailand, and Vietnam. In addition, the proportion of dengue
events observed in the vaccine and placebo groups during the rainy season is higher than the
proportion of the year that is defined as the rainy season (Table 1). For example, in CYD14 at
the Sao Pablo City site in the Philippines, 80% of the total number of dengue cases were
observed to occur during the rainy season, which comprised 42% of the year. Fig 2 shows the
attack rate by month in the placebo (2A) and vaccinated (2B) groups of CYD15 from June
2011 (start of enrollment) to mid-2014. The seasonal trend observed in CYD15 is less obvious,
although more infections appear to have occurred from April-May and September-November.
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These periods correspond to the rainy seasons of certain sites in Colombia, where 41% of the
dengue cases occurred. The seasonal trend in dengue attack rates may be less apparent in
CYD15 because the CYD15 sites covered a larger geographical area and the rainy seasons were
less similar than in the CYD14 sites (Fig 3A and 3B). The results of the descriptive analysis
indicate that our definition of rainy season corresponds to periods of higher observed rates of
dengue in CYD14 and in CYD15. Together, these data suggest that rainy season could be a rea-
sonable proxy measurement for periods of increased dengue risk.
Dengue disease incidence patterns observed in both studies are similar to patterns seen in
national dengue surveillance data (Supplemental Material S2.2.4.7, ref [49]). The seasonal
trends seen in the monthly attack rates of the placebo groups of each study corresponded with
the rainy seasons defined based on the WMO data, suggesting the rainy season represents a
period of increased dengue disease. We therefore assumed that if rainfall data had been col-
lected in the studies, the resulting rainy season definitions would not differ substantially from
those calculated from the WMO data.
Vaccine efficacy against symptomatic, virologically-confirmed dengue did not change dur-
ing the rainy season. In CYD14, the estimated VE during the rainy season was 55.8% with 95%
CI = (46.9%, 64.6%) and 53.2% with 95% CI = (38.6%, 64.3%) during the non-rainy season. In
CYD15, the estimated VE during the rainy season was 64.1% with 95% CI = (57.7%, 70.6%)
Fig 1. Dengue attack rate by 30-day period in placebo and vaccinated groups of CYD14. (A) Dengue attack rate by 30-day period
in placebo group of CYD14. (B) Dengue attack rate by 30-day period in vaccinated group of CYD14.
https://doi.org/10.1371/journal.pone.0207878.g001
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and 66.7% with 95% CI = (54.8%, 75.5%) during the non-rainy season. The estimated VEs
from the models that included rainy season were almost identical to those from previous anal-
yses [9,10]: 54.9% with 95% CI = (47.0%, 61.6%) for CYD14 and 64.8% with 95% CI = (58.9%,
68.8%) for CYD15. The results from the time-dependent Cox models that include or do not
include an interaction term for vaccine and rainy season are shown in Tables 2 and 3 for
CYD14 and CYD15, respectively. Specifically, the Cox models with time-dependent rainy sea-
son showed no significant modification of VE by rainy season in either study and no signifi-
cant modification in the combined analysis (interaction p-values = 0.74 and 0.69 for CYD14
and CYD15). Rainy season was a strong significant correlate of dengue in the vaccine and pla-
cebo groups in each study [hazard ratio (HR) = 2.11 with 95% CI = (1.75, 2.54) in CYD14 and
HR = 3.08 with 95% CI = (2.58, 3.67) in CYD15]. Age was also significantly associated with
dengue in both CYD14 and CYD15, a finding consistent with previous analyses showing that
younger children are at higher risk of symptomatic, virologically-confirmed dengue [9,10]. In
addition, country was significantly associated with dengue in both studies (global p-
values< 0.01).
The results from the combined CYD14 and CYD15 analysis (S2 Table) were consistent
with the individual trial analyses: risk of dengue was significantly higher during the rainy sea-
son (HR = 2.88 with 95% CI = (2.48, 3.35)) and rainy season did not modify VE (interaction p-
Fig 2. Dengue attack rate by 30-day period in placebo and vaccinated groups of CYD15. (A) Dengue attack rate by 30-day period
in placebo group of CYD15. (B) Dengue attack rate by 30-day period in vaccinated group of CYD15.
https://doi.org/10.1371/journal.pone.0207878.g002
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value = 0.74). In addition, the effect of rainy season did not differ by study (interaction p-
value = 0.60). The combined analysis also showed that study was significantly associated with
dengue (p-value < 0.01), with a 30% lower risk of dengue in CYD15 compared to CYD14.
This may be explained by the higher risk of dengue associated with the different geographical
locations of the studies.
Discussion
The risk of dengue was significantly higher during the rainy season in the vaccine and placebo
groups of each of the phase III trials and in the combined CYD14 and CYD15 analysis, indicat-
ing that our definition of rainy season may serve as a proxy for periods of increased dengue
transmission. Importantly, CYD-TDV VE did not vary by rainy season in any of the analyses,
suggesting that VE is not expected to change during periods of high transmission in endemic
regions. One important caveat to be noted is that rainfall data were not collected in the CYD14
and CYD15 studies themselves, but were obtained from publicly available data from the
National Meteorological & Hydrological Services in the individual countries. Although these
data are likely less accurate than site-level data collection in the trial, the National Meteorologi-
cal and Hydrological Services data were of sufficient accuracy to define a binary rainy season
variable at the site level that we found to be a strong correlate of risk of dengue in both the
CYD14 and CYD15 trials, stronger than any other variable considered. However, as the rainy
season variable was considered as a binary variable, we are unable to account for the intensity
of the rainfall during given time periods. Precipitation can have complex effects on mosquito
abundance (and therefore infection force), since moderate rain increases potential breeding
Fig 3. Rainy season of all trials sites (data from World Meteorological Organization). (A) Rainy season of CYD14 sites. (B) Rainy
season of CYD15 sites.
https://doi.org/10.1371/journal.pone.0207878.g003
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grounds but heavy rain may wash out immature mosquito populations [50]. Thus, it may be
informative to prospectively collect infection parameters in future studies as they could pro-
vide more precise estimates of force of infection than our rainy season variable. In particular,
the effect of the volume and/or intensity of the rainy season could be investigated as this would
provide information not captured by the dichotomous rainy season variable we considered.
Other markers such as placebo incidence or mosquito density could also be considered in the
model for measuring the force of infection. Here, rainfall data was used because it could be eas-
ily obtained for a public database and we were expected less measurement error in this variable
than other measures. Moreover, the existing literature has not established a clear relationship
between mosquito density and dengue infection [51]. Still, another potential approach could
be to measure mosquito density and consider it as an effect modifier of vaccine efficacy. A
more complex analysis could also account for other factors influencing VE. In particular,
Table 1. Rainy season (RS) and dengue by country and site in CYD14 and CYD15.
Study Country Site % of the year that is rainy season No. of dengue events during RS / No. of total dengue events (%)
CYD14 Indonesia Jakarta 33% 8/29 (28%)
Bandung 33% 19/39 (49%)
Bali 42% 9/15 (60%)
Malaysia Kuala Lumpur 50% 11/23 (48%)
Penang 42% 3/7 (43%)
Philippines San Pablo City 42% 109/136 (80%)
Cebu City 58% 113/157 (72%)
Thailand Kamphaeng Phet Province; 50% 12/32 (38%)
Ratchaburi Province 50% 41/57 (72%)
Vietnam Long Xuyen 50% 36/59 (61%)
My Tho 50% 25/41 (61%)
CYD15 Brazil Vitória 42% 17/30 (57%)
Natal 42% 27/29 (93%)
Goiania 50% 14/16 (88%)
Campo Grande 42% 20/24 (83%)
Fortaleza 42% 16/20 (83%)
Colombia Yopal 58% 52/77 (68%)
Aguazul 42% 65/78 (83%)
Acacias 50% 22/43 (51%)
Girardot 58% 14/22 (64%)
Calarcá 50% 3/7 (43%)
La Tebaida 50% 0/0
Montenegro 50% 0/2
Armenia 50% 2/5 (40%)
Bucaramanga 50% 23/38 (61%)
Honduras Tegucigalpa 50% 94/113 (83%)
Mexico México 42% 60/77 (78%)
Veracruz 42% 19/22 (86%)
Tamaulipas 42% (75%)
Tizimin 42% 12/16 (75%)
Valladolid 42% 13/15 (87%)
Puerto Rico San Juan 75% 3/8 (38%)
Guayama 75% 13/16 (82%)
https://doi.org/10.1371/journal.pone.0207878.t001
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given the recent findings on the baseline serostatus, the model could be improved by adjusting
on this covariate as well.
In the combined analysis of 9–16 years-olds, we found significant different risks of dengue
between the studies CYD14 and CYD15; moreover, country was significantly associated with
dengue within each study. We investigated whether these findings were due to a difference in
the effect of rainy season on dengue in the different age groups of the two studies. We found
that no significant effect modification by age on rainy season in either the CYD14 or CYD15
analyses (S3 and S4 Tables respectively), suggesting that the effect of the rainy season was the
same on children of all ages within the study ranges. We also performed similar analyses on
children aged 9 years and older in CYD14 and found that the increased risk of dengue during
the rainy season was similar to that in the all-age CYD14 analysis, suggesting that the increased
risk of dengue during the rainy season is similar across the age range in the trials. To more pre-
cisely determine how the effect of rainy season varies by geographic location, it would be infor-
mative to explore the impact of rainy season within different countries or sites; however, the
small number of cases precludes this type of analysis. We hypothesize that observed differences
in dengue incidence by site, country, and/or study may reflect different average monthly and/
or annual precipitation levels at the different trial sites. A better understanding of the patterns
of rainy season on a more local scale would help guide public health policies and would justify
strengthened preventive measures at given periods of the year.
Our analyses were performed on the intention-to-treat cohort as this cohort preserves the
benefits of randomization and ensures unbiased results. Similar results are expected for the
per-protocol cohort for two reasons: first, more than 95% of the subjects in both studies
Table 2. Estimated coefficients, standard errors, hazard ratios and their 95% CIs from time-dependent Cox models in CYD14, with or without the vaccine by rainy
season interaction where the interaction term is included to assess effect modification of rainy season on VE.













Vaccine -0.80 (0.082) 0.45 (0.38, 0.53) < 0.001 - -0.76 (0.14) 0.47 (0.36, 0.61)2 < 0.001 -
Age < 0.001 < 0.001
2–5 reference reference - reference reference -
6–11 -0.31 (0.092) 0.73 (0.61, 0.88) < 0.001 -0.31 (0.092) 0.73 (0.61, 0.88) < 0.001
12–14 -0.85 (0.13) 0.43 (0.33, 0.55) < 0.001 -0.85 (0.13) 0.43 (0.33, 0.55) < 0.001
Male -0.064 (0.082) 0.94 (0.80, 1.10) 0.43 - -0.064 (0.082) 0.94 (0.80, 1.10) 0.43 -
Country < 0.001 < 0.001
Indonesia reference reference - reference reference -
Malaysia -0.79 (0.21) 0.46 (0.30, 0.69) < 0.001 -0.79 (0.21) 0.46 (0.30, 0.69) < 0.001
Philippines 0.57 (0.13) 1.77 (1.38, 2.28) < 0.001 0.57 (0.13) 1.77 (1.38, 2.28) < 0.001
Thailand 0.42 (0.15) 1.52 (1.12, 2.05) 0.007 0.42 (0.15) 1.52 (1.12, 2.05) 0.007
Vietnam -0.14 (0.15) 0.87 (0.65, 1.17) 0.36 -0.14 (0.15) 0.87 (0.65, 1.17) 0.36
Rainy season-3 0.75 (0.096) 2.11 (1.75, 2.54) < 0.001 - 0.77 (0.13) 2.17 (1.69, 2.78) < 0.01 -
Vaccine:Rainy season
interaction
- - - -0.056 (0.17) 0.95 (0.67, 1.32)4 0.74 -
CI, confidence interval.
1For models with categorical variables, the global test assessed whether all the hazard ratios for each category were equal to 1.
2Hazard ratio (vaccine/placebo) for the non-rainy season (reference Rainy season category).
3Rainy season was site-specific, as defined in Table 1, and the reference category was the non-rainy season.
4Hazard ratio (rainy/non-rainy season) for the vaccine group divided by hazard ratio (rainy/non-rainy season) for the placebo group.
https://doi.org/10.1371/journal.pone.0207878.t002
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received 3 doses of the vaccine, and then, the VE in the per-protocol cohort has been shown to
be nearly identical to VE among participants who had received one or more injections [9,10].
In conclusion, dengue poses a greater risk during the rainy season when large populations
of A. aegypti and A. albopictus mosquitoes exhibit a high degree of contact with humans.
Despite this increase in risk of dengue during the rainy season, there was no evidence to indi-
cate that VE is lower during these periods of increased dengue risk in endemic regions.
Supporting information
S1 File. Cox model equation for the combined analysis.
(PDF)
S1 Fig. Map of the study sites. Taken from Guy B, Briand O, Lang J, Saville M, Jackson N.
Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. Vac-
cine. 2015 Dec 10;33(50):7100–11.
(TIFF)
S1 Table. Demographic characteristics of the population of the CYD14 and CYD15 com-
bined analysis.
(PDF)
S2 Table. Estimated hazard ratios and 95% CIs for time-dependent Cox models in com-
bined CYD14 and CYD15, without any interaction, with the vaccine by rainall interaction
only, with the study by rainfall interaction and with both interactions.
(PDF)
Table 3. Estimated coefficients, standard errors, hazard ratios and their 95% CIs for time-dependent Cox models in CYD15, with or without the vaccine by rainy
season interaction where the interaction term is included to assess effect modification of rainy season on VE.













Vaccine -1.04 (0.079) 0.35 (0.30, 0.41) < 0.001 - -1.10 (0.16) 0.33 (0.25, 0.45)2 < 0.001 -
Age
9–11 reference reference - reference reference -
12–16 -0.24 (0.078) 0.79 (0.67, 0.92) 0.002 -0.24 (0.078) 0.79 (0.67, 0.92) 0.002
Male 0.18 (0.078) 1.20 (1.03, 1.40) 0.02 - 0.18 (0.078) 1.20 (1.03, 1.40) 0.02 -
Country < 0.001 < 0.001
Brazil reference reference - reference reference -
Colombia -0.28 (0.11) 0.75 (0.61, 0.94) 0.01 -0.28 (0.11) 0.76 (0.61, 0.94) 0.01
Honduras 0.096 (0.13) 1.10 (0.85, 1.43) 0.47 0.096 (0.13) 1.10 (0.85, 1.43) 0.47
Mexico 0.14 (0.13) 1.15 (0.90, 1.47) 0.28 0.14 (0.13) 1.15 (0.90, 1.47) 0.28
Puerto Rico -0.81 (0.22) 0.46 (0.29, 0.69) < 0.001 -0.81 (0.22) 0.45 (0.29, 0.69) < 0.001
Rainy season3 1.13 (0.090) 3.08 (2.58, 3.67) < 0.001 - 1.09 (0.12) 2.99 (2.38, 3.76) < 0.001 -
Vaccine:Rainy season
interaction
- - - 0.073 (0.18) 1.08 (0.75, 1.53)4 0.69 -
CI, confidence interval.
1For models with categorical variables, the global test assessed whether all the hazard ratios for each category were equal to 1.
2Hazard ratio (vaccine/placebo) for the non-rainy season (reference Rainy season category).
3Rainy season was site-specific, as defined in Table 2, and the reference category was the non-rainy season.
4Hazard ratio (rainy/non-rainy season) for the vaccine group divided by hazard ratio (rainy/non-rainy season) for the placebo group.
https://doi.org/10.1371/journal.pone.0207878.t003
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S3 Table. Estimated hazard ratios and 95% CIs for time-dependent Cox models in CYD14,
with or without the age category by rainy season interaction where the interaction term is
included to assess effect modification of age on rainy season.
(PDF)
S4 Table. Estimated hazard ratios and 95% CIs for time-dependent Cox models in CYD15,
with or without the age category by rainy season interaction where the interaction term is
included to assess effect modification of age on rainy season.
(PDF)
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